CN116568301A - 用于治疗疾病的双环化合物及其用途 - Google Patents
用于治疗疾病的双环化合物及其用途 Download PDFInfo
- Publication number
- CN116568301A CN116568301A CN202180079749.8A CN202180079749A CN116568301A CN 116568301 A CN116568301 A CN 116568301A CN 202180079749 A CN202180079749 A CN 202180079749A CN 116568301 A CN116568301 A CN 116568301A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- alkyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411623883.1A CN119684295A (zh) | 2020-11-02 | 2021-11-01 | 用于治疗疾病的双环化合物及其用途 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063108660P | 2020-11-02 | 2020-11-02 | |
| US63/108,660 | 2020-11-02 | ||
| PCT/US2021/057563 WO2022094400A1 (en) | 2020-11-02 | 2021-11-01 | Bicyclic compounds and uses thereof for the treatment of diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411623883.1A Division CN119684295A (zh) | 2020-11-02 | 2021-11-01 | 用于治疗疾病的双环化合物及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116568301A true CN116568301A (zh) | 2023-08-08 |
Family
ID=81384389
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180079749.8A Pending CN116568301A (zh) | 2020-11-02 | 2021-11-01 | 用于治疗疾病的双环化合物及其用途 |
| CN202411623883.1A Pending CN119684295A (zh) | 2020-11-02 | 2021-11-01 | 用于治疗疾病的双环化合物及其用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411623883.1A Pending CN119684295A (zh) | 2020-11-02 | 2021-11-01 | 用于治疗疾病的双环化合物及其用途 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240025903A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4236944A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7884275B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230104191A (cg-RX-API-DMAC7.html) |
| CN (2) | CN116568301A (cg-RX-API-DMAC7.html) |
| AR (1) | AR124637A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021371026A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3196582A1 (cg-RX-API-DMAC7.html) |
| CL (2) | CL2023001195A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL302465A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023004942A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI918751B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022094400A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL313039A (en) * | 2021-12-17 | 2024-07-01 | Athira Pharma Inc | Uses of bicyclic compounds for the treatment of diseases |
| KR20250005323A (ko) * | 2022-05-04 | 2025-01-09 | 아티라 파마, 인코포레이티드 | 신경병증을 치료하는 방법 |
| US20250275976A1 (en) * | 2022-05-04 | 2025-09-04 | Athira Pharma, Inc. | Methods of Treating Neuroinflammatory Conditions |
| JP2025538382A (ja) | 2022-11-18 | 2025-11-28 | アティラ・ファーマ・インコーポレイテッド | 炎症病態を治療する方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184223B1 (en) * | 1995-10-27 | 2001-02-06 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
| WO2004035587A1 (en) | 2002-10-17 | 2004-04-29 | Myriad Genetics, Inc. | Reverse-turn mimetics and composition and methods relating thereto |
| US7192976B2 (en) * | 2002-12-21 | 2007-03-20 | Angion Biomedica Corporation | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| WO2006036981A2 (en) * | 2004-09-28 | 2006-04-06 | Angion Biomedica Corp. | Small molecule modulators of cytokine activity |
| US7879898B1 (en) * | 2006-02-14 | 2011-02-01 | Angion Biomedica Corp. | Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease |
| EP1947085A1 (en) * | 2007-01-19 | 2008-07-23 | Laboratorios del Dr. Esteve S.A. | Substituted indole sulfonamide compounds, their preparation and use as medicaments |
| US8691819B2 (en) * | 2008-10-14 | 2014-04-08 | Prism Biolab Corporation | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions |
| US20160074400A1 (en) * | 2012-08-06 | 2016-03-17 | University Of Southern California | Wnt modulators for the protection, mitigation and treatment of radiation injury |
| EP3366687B1 (en) * | 2015-09-18 | 2020-04-29 | National University Corporation Tottori University | Suppression and regeneration promoting effect of low molecular weight compound on cancer and fibrosis |
-
2021
- 2021-11-01 AU AU2021371026A patent/AU2021371026A1/en active Pending
- 2021-11-01 EP EP21887720.7A patent/EP4236944A4/en active Pending
- 2021-11-01 US US18/032,918 patent/US20240025903A1/en active Pending
- 2021-11-01 MX MX2023004942A patent/MX2023004942A/es unknown
- 2021-11-01 TW TW110140600A patent/TWI918751B/zh active
- 2021-11-01 JP JP2023551946A patent/JP7884275B2/ja active Active
- 2021-11-01 IL IL302465A patent/IL302465A/en unknown
- 2021-11-01 AR ARP210103033A patent/AR124637A1/es unknown
- 2021-11-01 KR KR1020237018061A patent/KR20230104191A/ko active Pending
- 2021-11-01 CN CN202180079749.8A patent/CN116568301A/zh active Pending
- 2021-11-01 CA CA3196582A patent/CA3196582A1/en active Pending
- 2021-11-01 WO PCT/US2021/057563 patent/WO2022094400A1/en not_active Ceased
- 2021-11-01 CN CN202411623883.1A patent/CN119684295A/zh active Pending
-
2023
- 2023-04-26 CL CL2023001195A patent/CL2023001195A1/es unknown
-
2024
- 2024-02-02 CL CL2024000340A patent/CL2024000340A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4236944A1 (en) | 2023-09-06 |
| TWI918751B (zh) | 2026-03-21 |
| CL2024000340A1 (es) | 2024-08-16 |
| US20240025903A1 (en) | 2024-01-25 |
| CN119684295A (zh) | 2025-03-25 |
| CA3196582A1 (en) | 2022-05-05 |
| AU2021371026A1 (en) | 2023-06-15 |
| JP2023550543A (ja) | 2023-12-01 |
| AU2021371026A9 (en) | 2024-04-18 |
| JP7884275B2 (ja) | 2026-07-03 |
| KR20230104191A (ko) | 2023-07-07 |
| AR124637A1 (es) | 2023-04-19 |
| IL302465A (en) | 2023-06-01 |
| CL2023001195A1 (es) | 2023-10-20 |
| TW202233622A (zh) | 2022-09-01 |
| MX2023004942A (es) | 2023-07-06 |
| EP4236944A4 (en) | 2024-09-04 |
| WO2022094400A1 (en) | 2022-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN119684295A (zh) | 用于治疗疾病的双环化合物及其用途 | |
| CN107001378A (zh) | 吡咯并嘧啶化合物 | |
| EP4598907A1 (en) | Phenyl oxy amide kinase inhibitors | |
| KR20240121239A (ko) | 질환 치료를 위한 이환식 화합물의 용도 | |
| JP2025515045A (ja) | 神経炎症病態を治療する方法 | |
| EP4518866A1 (en) | Methods of treating fibrosis | |
| CN118382441A (zh) | 双环化合物用于治疗疾病的用途 | |
| HK40122844A (en) | Bicyclic compounds and uses thereof for the treatment of diseases | |
| EA049703B1 (ru) | Бициклические соединения и их применение для лечения заболеваний | |
| HK40113746A (en) | Uses of bicyclic compounds for the treatment of diseases | |
| HK40097563A (en) | Bicyclic compounds and uses thereof for the treatment of diseases | |
| CN119300834A (zh) | 治疗神经病变的方法 | |
| EA050745B1 (ru) | Применение бициклических соединений для лечения заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40097563 Country of ref document: HK |
|
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Country or region after: U.S.A. Address after: Washington State Applicant after: Liona Biotechnology Co.,Ltd. Address before: Washington State Applicant before: Yasina Pharmaceutical Co. Country or region before: U.S.A. |